|
|
Article: Phase 3 Psoriatic Arthritis Data for ENBREL(R) (etanercept) Announced at a National Scientific Meeting.
- Article from:
- PR Newswire
- Article date:
- November 12, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Application for ENBREL Granted Priority Review by FDA as First Product
To Be Considered for Treatment of Psoriatic Arthritis
SAN FRANCISCO, Nov. 11 /PRNewswire/ --
Phase 3 results of ENBREL(R) (etanercept) studied in patients with psoriatic arthritis will be presented this week at the 65th Annual American College of Rheumatology National Scientific Meeting in San Francisco.
"Psoriatic arthritis is a devastating disease for which there are currently no approved treatments," says Philip Mease, MD, Seattle Rheumatology Associates, Swedish Medical Center Division of Clinical Research and Clinical Professor, University of Washington. ...